Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 976 to 990 of 1362 results for social care

  1. Ledipasvir–sofosbuvir for treating chronic hepatitis C (TA363)

    Evidence-based recommendations on ledipasvir–sofosbuvir (Harvoni) for treating some types (genotypes) of chronic hepatitis C.

    Technology appraisal guidance
    Published
    25 November 2015
    View recommendations

    Sections for TA363

  2. Lebrikizumab for treating moderate to severe atopic dermatitis in people 12 years and over (TA986)

    Evidence-based recommendations on lebrikizumab (Ebglyss) for treating moderate to severe atopic dermatitis in people 12 years and over.

    Technology appraisal guidance
    Published
    10 July 2024
    View recommendations

    Sections for TA986

  3. Axicabtagene ciloleucel for treating diffuse large B-cell lymphoma and primary mediastinal large B-cell lymphoma after 2 or more systemic therapies (TA872)

    Evidence-based recommendations on axicabtagene ciloleucel (Yescarta) for treating diffuse large B-cell lymphoma and primary mediastinal large B-cell lymphoma in adults after 2 or more systemic therapies.

    Technology appraisal guidance
    Published
    28 February 2023

    Sections for TA872

  4. Botulinum toxin type A for the prevention of headaches in adults with chronic migraine (TA260)

    Evidence-based recommendations on botulinum toxin type A (Botox) for preventing headaches in adults with chronic migraine.

    Technology appraisal guidance
    Published
    27 June 2012
    View recommendations

    Sections for TA260

  5. Rapid tests for group A streptococcal infections in people with a sore throat (HTG531)

    Evidence-based recommendations on rapid tests for group A streptococcal infections in people aged 5 and over with a sore throat.

    HealthTech guidance
    Published
    13 November 2019
    View recommendations

    Sections for HTG531

  6. Rimegepant for treating migraine (TA919)

    Evidence-based recommendations on rimegepant (Vydura) for the acute treatment of migraine in adults.

    Technology appraisal guidance
    Published
    18 October 2023
    View recommendations

    Sections for TA919

  7. Rituximab in combination with glucocorticoids for treating anti-neutrophil cytoplasmic antibody-associated vasculitis (TA308)

    Evidence-based recommendations on rituximab (MabThera) with glucocorticoids for treating anti-neutrophil cytoplasmic antibody-associated vasculitis in adults.

    Technology appraisal guidance
    Published
    26 March 2014
    View recommendations

    Sections for TA308

  8. Pegcetacoplan for treating geographic atrophy [ID4041]

    In development Reference number: GID-TA11351 Expected publication date: TBC

    Technology appraisal guidance
    In development

  9. Pembrolizumab with etoposide and a platinum-based compound for untreated extensive-stage small-cell lung cancer [ID1509]

    Discontinued Reference number: GID-TA10413

    Technology appraisal guidance
    Discontinued

  10. Axonics sacral neuromodulation system for faecal incontinence (MIB259)

    NICE has developed a medtech innovation briefing (MIB) on Axonics sacral neuromodulation system for faecal incontinence .

    Medtech innovation briefing
    Published
    4 May 2021

  11. Supporting family members, carers and staff:- What types of services or approaches are effective in supporting family members, carers and staffto be resilient and able to provide care and support to people with a learning disability and behaviour that challenges?

    supporting family members, carers and staffto be resilient and able to provide care and support to people with a learning disability and...

    Research recommendation
    Published
    15 November 2018

  12. Pembrolizumab for previously treated advanced hepatocellular carcinoma [ID1458]

    Discontinued Reference number: GID-TA10380

    Technology appraisal guidance
    Discontinued

  13. Pembrolizumab for previously treated metastatic triple negative breast cancer [ID1246]

    Discontinued Reference number: GID-TA10295

    Technology appraisal guidance
    Discontinued

  14. Oxyzyme and Iodozyme 2-layer hydrogel wound dressings with iodine for treating chronic wounds (MIB11)

    NICE has developed a Medtech Innovation Briefing (MIB) on Oxyzyme and Iodozyme 2-layer hydrogel wound dressings with iodine for treating chronic wounds

    Medtech innovation briefing
    Published
    19 November 2014

  15. Alere Afinion CRP for C-reactive protein testing in primary care (MIB81)

    NICE has developed a medtech innovation briefing (MIB) on the Alere Afinion CRP for C-reactive protein testing in primary care

    Medtech innovation briefing
    Published
    14 September 2016